Astrazeneca Study Shows Saphnelo Injection Reduces Lupus Disease Activity

MT Newswires Live01-06

Astrazeneca (AZN) said Tuesday that a late-stage trial of its drug Saphnelo demonstrated a significant decrease in symptoms for patients with systemic lupus erythematosus, a chronic autoimmune disease.

The study found that a subcutaneous injection of the medication helped more participants reach lower disease activity levels compared to a placebo after one year, the company said.

Secondary results showed that 56.2% of patients were able to maintain lower doses of oral steroids while sustaining clinical improvements, Astrazeneca said.

The safety results for the injectable version match up with previous data from the already approved intravenous form of the medicine, the company added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment